Peer-Reviewed Publication
Drug Deliv2026;33(1):2669030.December 31, 2026Journal Article
Gallic acid-driven core-shell nanovehicles enable intestinal adhesion and adipose retention for enhanced oral bioavailability of cholecalciferol.
Guangyu Fan1, Jixiang Zhao1, Ru Zhang1, Zhuo Li1, Haifeng Wu1,2,3,4, Yang Lu5, Ying Li1,2,3,4, Zhengqi Dong1,2,3,4
1State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
2Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
3Key Laboratory of New Drug Discovery Based on Classic Chinese Medicine Prescription, Beijing, China.
4Beijing Key Laboratory of Innovative Drug Discovery of Traditional Chinese Medicine (Natural Medicine) and Translational Medicine, Beijing, China.
5School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Abstract
Cholecalciferol (VDC), a vital form of vitamin D, is essential for maintaining calcium-phosphorus balance, promoting bone health, and regulating the immune system; however, its therapeutic potential is limited by low oral bioavailability and poor aqueous solubility. To address these issues, a multifunctional nanoparticle (NPS) was developed: VDC was first encapsulated in β-cyclodextrin (βCD) to fo…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans